Overview of a rational approach to design type I 17beta-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of Steroid Biochemistry and Molecular Biology

• Publication date

  1998-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0960-0760(98)00043-0PMID 9744515
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Affinity labeling of arginyl residues at the catalytic region of estradiol 17 beta-dehydrogenase from human placenta by 16-oxoestrone.

  2005cited by this paper
• Aromatase inhibitors — mechanisms of steroidal inhibitors

  2004cited by this paper
• The future of new pure antiestrogens in clinical breast cancer

  2004cited by this paper
• Second generation aromatase inhibitor — 4-hydroxyandrostenedione

  2004cited by this paper
• Vorozole, a specific non-steroidal aromatase inhibitor

  2004cited by this paper
• A 6beta-(thiaheptanamide) derivative of estradiol as inhibitor of 17beta-hydroxysteroid dehydrogenase type 1.

  1998cited by this paper
• C16 and C17 derivatives of estradiol as inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1: chemical synthesis and structure-activity relationships.

  1998cited by this paper
• A 6β-(thiaheptanamide) derivative of estradiol as inhibitor of 17β-hydroxysteroid dehydrogenase type 1

  1998cited by this paper
• The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology

  1997cited by this paper
• The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology.

  1997cited by this paper
• Intracellular regulation of 17 beta-hydroxysteroid dehydrogenase type 2 catalytic activity in A431 cells.

  1997cited by this paper
• The estradiol pharmacophore: ligand structure-estrogen receptor binding affinity relationships and a model for the receptor binding site.

  1997cited by this paper
• Synthesis and evaluation of estradiol derivatives with 16 alpha-(bromoalkylamide), 16 alpha-(bromoalkyl) or 16 alpha-(bromoalkynyl) side chain as inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1 without estrogenic activity.

  1996cited by this paper
• Crystal structure of human estrogenic 17β-hydroxysteroid dehydrogenase complexed with 17β-estradiol

  1996cited by this paper
• 17β-Hydroxysteroid dehydrogenase: inhibitors and inhibitor design

  1996cited by this paper
• Synthesis and evaluation of estradiol derivatives with 16α-(bromoalkylamide), 16α-(bromoalkyl) or 16α-(bromoalkynyl) side chain as inhibitors of 17β-hydroxysteroid dehydrogenase type 1 without estrogenic activity

  1996cited by this paper
• Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer.

  1996cited by this paper
• D-Ring alkylamine derivatives of estradiol: effect on er-binding affinity and antiestrogenic activity

  1996cited by this paper
• Synthesis of 16-[carbamoyl(bromomethyl)alkyl]estradiol: a potential dual-action inhibitor designed to blockade estrogen action and biosynthesis

  1996cited by this paper
• Aromatase inhibitors in clinical practice: current status and a look to the future.

  1996cited by this paper
• The structure of a complex of human 17beta-hydroxysteroid dehydrogenase with estradiol and NADP+ identifies two principal targets for the design of inhibitors.

  1996cited by this paper
• Crystal structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase complexed with 17 beta-estradiol.

  1996cited by this paper
• Synthesis of 16-(bromoalkyl)-estradiols having inhibitory effect on human placental estradiol 17 beta-hydroxysteroid dehydrogenase (17 beta-HSD type 1).

  1995cited by this paper
• Characteristics of human types 1, 2 and 3 17 beta-hydroxysteroid dehydrogenase activities: oxidation/reduction and inhibition.

  1995cited by this paper
• Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.

  1995cited by this paper
• Kinetic analysis of enzymic activities: prediction of multiple forms of 17 beta-hydroxysteroid dehydrogenase.

  1995cited by this paper
• Synthesis of 16-(bromoalkyl)-estradiols having inhibitory effect on human placental estradiol 17β-hydroxysteroid dehydrogenase (17-β-HSD type 1)

  1995cited by this paper
• The Estrogen Receptor as a Target for Rational Drug Design

  1995cited by this paper
• Role of 17β-hydroxysteroid dehydrogenase type 1 in endocrine and intracrine estradiol biosynthesis

  1995cited by this paper
• Structure of human estrogenic 17 beta-hydroxysteroid dehydrogenase at 2.20 A resolution.

  1995cited by this paper
• Molecular cloning of a novel widely expressed human 80 kDa 17 beta-hydroxysteroid dehydrogenase IV.

  1995cited by this paper
• ARIMIDEX: a new oral, once-a-day aromatase inhibitor.

  1995cited by this paper
• A Convenient Synthetic Method for Alpha-Alkylation of Steroidal 17-Ketone: Preparation of 16β(THPO-Heptyl)-Estradiol

  1995cited by this paper
• 16α-propyl derivatives of estradiol as inhibitors of 17β-hydroxysteroid dehydrogenase type 1

  1994cited by this paper
• Male pseudohermaphroditism caused by mutations of testicular 17β–hydroxysteroid dehydrogenase 3

  1994cited by this paper
• Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.

  1994cited by this paper
• Formestane: effective therapy in postmenopausal women with advanced breast cancer.

  1994cited by this paper
• N-butyl, N-methyl, 11-[3′,17′ β-(dihydroxy)-1′,3′,5′(10′)- estratrien-16′ α-yl]-9(R/S)-bromo undecanamide: synthesis and 17β-HSD inhibiting, estrogenic and antiestrogenic activities

  1994cited by this paper
• The Medicinal Chemistry of Nonsteroidal Antiestrogens: A Review

  1994cited by this paper
• N-butyl, N-methyl, 11-[3',17' beta-(dihydroxy)-1',3',5'(10')-estratrien-16' alpha-yl]-9(R/S)-bromo undecanamide: synthesis and 17 beta-HSD inhibiting, estrogenic and antiestrogenic activities.

  1994cited by this paper
• Aromatase inhibitors in the treatment of breast cancer.

  1994cited by this paper
• RU 58,668, a new pure antiestrogen inducing a regression of human mammary carcinoma implanted in nude mice.

  1994cited by this paper
• Structure, regulation and role of 3 beta-hydroxysteroid dehydrogenase, 17 beta-hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues.

  1994cited by this paper
• 11 Structure, regulation and role of 3β-hydroxysteroid dehydrogenase, 17β-hydroxysteroid dehydrogenase and aromatase enzymes in the formation of sex steroids in classical and peripheral intracrine tissues

  1994cited by this paper
• Expression cloning and characterization of human 17 beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity.

  1993cited by this paper
• DNA recognition by the oestrogen receptor: from solution to the crystal.

  1993cited by this paper
• Inhibition of estrone sulfatase and 17β-hydroxysteroid dehydrogenase by antiestrogens

  1993cited by this paper
• Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women.

  1993cited by this paper
• Effects of antioestrogens on the DNA binding activity of oestrogen receptors in vitro

  1992cited by this paper
• Novel compounds inhibit estrogen formation and action.

  1992cited by this paper
• Effects of antioestrogens on the DNA binding activity of oestrogen receptors in vitro.

  1992cited by this paper
• Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women.

  1992cited by this paper
• Distribution of 17 beta-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues.

  1992cited by this paper
• Distribution of 17β-hydroxysteroid dehydrogenase gene expression and activity in rat and human tissues

  1992cited by this paper
• Synthesis and biological activity of new halo-steroidal antiestrogens.

  1991cited by this paper
• Hydrogen bonding in steroidogenesis: studies on new heterocyclic analogs of estrone that inhibit human estradiol 17 beta-dehydrogenase.

  1991cited by this paper
• Synthesis and biological activity of 17a-alkynylamide derivatives of estradiol

  1991cited by this paper
• Endocrine therapy for prostate cancer.

  1991cited by this paper
• Intracrinology.

  1991cited by this paper
• Synthesis and biological activity of 17 alpha-alkynylamide derivatives of estradiol.

  1991cited by this paper
• The role of endocrine therapy in primary breast cancer.

  1990cited by this paper
• Characterization of cDNAs for human estradiol 17 beta-dehydrogenase and assignment of the gene to chromosome 17: evidence of two mRNA species with distinct 5'-termini in human placenta.

  1989cited by this paper
• Human placental estradiol 17 beta-dehydrogenase: evidence for inverted substrate orientation ("wrong-way" binding) at the active site.

  1988cited by this paper
• Estrogen receptor binding tolerance of 16 alpha-substituted estradiol derivatives.

  1988cited by this paper
• Steroidal pure antioestrogens.

  1987cited by this paper
• A short, stereoselective route to 16.alpha.-(substituted-alkyl)estradiol derivatives

  1987cited by this paper
• The affinity alkylators, 11α-bromoacetoxyprogesterone and estrone 3-bromoacetate, modify a common histidyl residue in the active site of human placental 17β,20α-hydroxysteroid dehydrogenase

  1986cited by this paper
• The affinity alkylators, 11 alpha-bromoacetoxyprogesterone and estrone 3-bromoacetate, modify a common histidyl residue in the active site of human placental 17 beta,20 alpha-hydroxysteroid dehydrogenase.

  1986cited by this paper
• Mechanism-based inactivation of 17 beta,20 alpha-hydroxysteroid dehydrogenase by an acetylenic secoestradiol.

  1986cited by this paper
• 17β-Hydroxysteroid and 20α-hydroxysteroid dehydrogenase activities of human placental microsomes: Kinetic evidence for two enzymes differing in substrate specificity

  1985cited by this paper
• 17 beta-hydroxysteroid and 20 alpha-hydroxysteroid dehydrogenase activities of human placental microsomes: kinetic evidence for two enzymes differing in substrate specificity.

  1985cited by this paper
• In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway.

  1984cited by this paper
• Inactivation of human placental 17 beta,20 alpha-hydroxysteroid dehydrogenase by 16-methylene estrone, an affinity alkylator enzymatically generated from 16-methylene estradiol-17 beta.

  1983cited by this paper
• Human placental 17 beta-estradiol dehydrogenase and 20 alpha-hydroxysteroid dehydrogenase. Two activities at a single enzyme active site.

  1981cited by this paper
• Photoaffinity labeling of human placental estradiol dehydrogenase with 3-(arylazido-beta-alanine)estrone.

  1980cited by this paper
• Synthesis of 2-bromoacetamidoestrone methyl ether and study of the steroid-binding site of human placental estradiol 17 beta-dehydrogenase.

  1980cited by this paper
• Synthesis and biochemical evaluation of inhibitors of estrogen biosynthesis.

  1978cited by this paper
• Synthesis of 4-bromoacetamidoestrone methyl ether and study of the steroid binding site of human placental estradiol 17beta-dehydrogenase.

  1978cited by this paper
• Synthesis of 16alpha-bromoacetoxyestradiol 3-methyl ether and study of the steroid binding site of human placental estradiol 17beta-dehydrogenase.

  1975cited by this paper

• Recent advances in the development of 17beta-hydroxysteroid dehydrogenase inhibitors.

  2024cites this paper
• Description of Chemical Synthesis, Nuclear Magnetic Resonance Characterization and Biological Activity of Estrane-Based Inhibitors/Activators of Steroidogenesis

  2023cites this paper
• Chemical Synthesis and Biological Evaluation of 3-Substituted Estrone/Estradiol Derivatives as 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors Acting via a Reverse Orientation of the Natural Substrate Estrone

  2023cites this paper
• Steroidal ferrocenes as potential enzyme inhibitors of the estrogen biosynthesis

  2020cites this paper
• Inhibitors of 17β-hydroxysteroid dehydrogenase type 1, 2 and 14: Structures, biological activities and future challenges.

  2019cites this paper
• Structure-biological function study of 17B-hydroxysteroid dehydrogenase type 1 and reductive steroid enzymes : inhibitor design targeting estrogen-dependent diseases

  2019cites this paper
• Synthèse sur support solide de dérivés aminostéroïdiens pour le développement d'agents anticancéreux et synthèse d'inhibiteurs stéroïdiens de la CYP1B1, une enzyme présentant un potentiel comme cible thérapeutique

  2018cites this paper
• Combined Biophysical Chemistry Reveals a New Covalent Inhibitor with a Low-Reactivity Alkyl Halide.

  2018cites this paper
• Structural insights into anticancer activity of D-ring modified estrone derivatives using their lipophilicity in estimation of SAR and molecular docking studies.

  2017cites this paper
• Comparative investigation of the in vitro inhibitory potencies of 13-epimeric estrones and D-secoestrones towards 17β-hydroxysteroid dehydrogenase type 1

  2016cites this paper
• A New Nonestrogenic Steroidal Inhibitor of 17β-Hydroxysteroid Dehydrogenase Type I Blocks the Estrogen-Dependent Breast Cancer Tumor Growth Induced by Estrone

  2012cites this paper
• Esteroides antitumorais: desenvolvimento e avaliação biológica de esteroides estrogénicos potencialmente úteis no tratamento do cancro da mama

  2012cites this paper
• Chemical synthesis of the 17-propanamide derivatives of stereoisomeric Δ14-17α- and 17β-estradiols: potential 17β-hydroxysteroid dehydrogenase inhibitors.

  2011cites this paper
• Convergent stereoselective and efficient synthesis of furanic-steroid derivatives

  2011cites this paper
• Contribution to the development of inhibitors of 17β-hydroxysteroid dehydrogenase types 1 and 7: key tools for studying and treating estrogen-dependent diseases.

  2011cites this paper
• Chemical synthesis, characterisation and biological evaluation of furanic-estradiol derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 1.

  2011cites this paper
• Overview of a Rational Approach to Design Type I 17β-Hydroxysteroid Dehydrogenase Inhibitors Without Estrogenic Activity: Chemical Synthesis and Biological Evaluation

  2010cites this paper
• 17ß-hydroxysteroid dehydrogenase inhibitors.

  2010cites this paper
• Preparation of 16β-Estradiol Derivative Libraries as Bisubstrate Inhibitors of 17β-Hydroxysteroid Dehydrogenase Type 1 Using the Multidetachable Sulfamate Linker

  2010cites this paper
• 17β-Hydroxysteroid dehydrogenase inhibitors: a patent review

  2010cites this paper
• Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.

  2009cites this paper
• Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives.

  2008cites this paper
• Chemical Synthesis of (S)‐Spiro(estradiol‐17,2′‐[1,4]oxazinan)‐6′‐one Derivatives Bearing Two Levels of Molecular Diversity

  2008cites this paper
• A 3D QSAR Model of 17β‐HSD1 Inhibitors Based on a Thieno[2,3‐d]pyrimidin‐4(3H)‐one Core Applying Molecular Dynamics Simulations and Ligand–Protein Docking

  2008cites this paper
• Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis.

  2008cites this paper
• Estradiol and estrone C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: blocking of ER+ breast cancer cell proliferation induced by estrone.

  2008cites this paper
• Chemical Synthesis, 17β-Hydroxysteroid Dehydrogenase Type 1 Inhibitory Activity and Assessment of In Vitro and In Vivo Estrogenic Activities of Estradiol Derivatives

  2008cites this paper
• New cancer drugs targeting the biosynthesis of estrogens and androgens

  2008cites this paper
• The Enzymatic Systems in the Formation and Transformation of Estrogens in Normal and Cancerous Human Breast: Control and Potential Clinical Applications

  2008cites this paper
• Synthesis, Reactivity and Biological Activity of 17β-HSD1 Inhibitors Based on a Thieno[2,3-d]pryrimidin-4(3H)-one Core

  2007cites this paper
• Solid-phase organic synthesis (SPOS) of modulators of estrogenic and androgenic action.

  2006cites this paper
• Inhibitory effects of fluorine-substituted estrogens on the activity of 17beta-hydroxysteroid dehydrogenases.

  2006cites this paper
• Focused Libraries of 16‐Substituted Estrone Derivatives and Modified E‐Ring Steroids: Inhibitors of 17ß‐Hydroxysteroid Dehydrogenase Type 1

  2006cites this paper
• 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines.

  2006cites this paper
• Evaluation of inhibitors for 17β-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme

  2006cites this paper
• Estrone and estradiol C-16 derivatives as inhibitors of type 1 17beta-hydroxysteroid dehydrogenase.

  2006cites this paper
• Anti-hormone Therapy: Principles of Endocrine Therapy of Cancer

  2006cites this paper
• Synthesis of Libraries of 16β‐Aminopropyl Estradiol Derivatives for Targeting Two Key Steroidogenic Enzymes

  2006cites this paper
• Estrogen-induced loss of progesterone receptor expression in normal and malignant ovarian surface epithelial cells

  2005influential citation
• Solid-phase synthesis of model libraries of 3 α17β-dihydroxy-16α-(aminoethyl-N-substituted)-5α-androstanes for the development of steroidal therapeutic agents

  2005cites this paper
• E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1.

  2005cites this paper
• Solid-phase synthesis of model libraries of 3alpha,17beta-dihydroxy-16alpha-(aminoethyl-N-substituted)-5alpha-androstanes for the development of steroidal therapeutic agents.

  2005cites this paper
• Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors.

  2005cites this paper
• Inhibitors of type 1 17β-hydroxysteroid dehydrogenase with reduced estrogenic activity: Modifications of the positions 3 and 6 of estradiol

  2005cites this paper
• Estradiol-adenosine hybrid compounds designed to inhibit type 1 17beta-hydroxysteroid dehydrogenase.

  2005cites this paper
• Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.

  2005cites this paper
• The selective estrogen enzyme modulators in breast cancer: a review.

  2004cites this paper
• Synthesis of simplified hybrid inhibitors of type 1 17beta-hydroxysteroid dehydrogenase via cross-metathesis and sonogashira coupling Reactions.

  2004cites this paper
• Cinnamic acid esters as potent inhibitors of fungal 17beta-hydroxysteroid dehydrogenase--a model enzyme of the short-chain dehydrogenase/reductase superfamily.

  2004cites this paper
• Inhibitors of 17 beta-hydroxysteroid dehydrogenases.

  2003cites this paper
• Synthesis of a First Estradiol-Adenosine Hybrid Compound

  2003cites this paper
• D-ring modified estrone derivatives as novel potent inhibitors of steroid sulfatase.

  2003cites this paper
• 17-beta-Hydroxysteroid dehydrogenase type 1: computational design of active site inhibitors targeted to the Rossmann fold.

  2003cites this paper
• 17-β-Hydroxysteroid dehydrogenase type 1: computational design of active site inhibitors targeted to the Rossmann fold

  2003cites this paper
• Actividad citocromo P450 aromatasa en la lubina ("Dicentrarchus Labrax" L.)

  2003cites this paper
• A multidetachable sulfamate linker successfully used in a solid-phase strategy to generate libraries of sulfamate and phenol derivatives.

  2002cites this paper
• Androsterone Derivatives Substituted at Position 16: Chemical Synthesis, Inhibition of Type 3 17β-hydroxysteroid Dehydrogenase, Binding Affinity for Steroid Receptors and Proliferative/antiproliferative Activity on Shionogi (AR +) Cells

  2002cites this paper
• A concerted, rational design of type 1 17β‐hydroxysteroid dehydrogenase inhibitors: estradiol‐adenosine hybrids with high affinity

  2002cites this paper
• Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer

  2002cites this paper
• Cutaneous androgen metabolism: basic research and clinical perspectives.

  2002cites this paper
• Aromatase inhibitors and other novel agents in breast cancer treatment

  2002cites this paper
• Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers

  2001cites this paper
• Inhibitors of type II 17beta-hydroxysteroid dehydrogenase.

  2001cites this paper
• Mechanisms of estradiol inactivation in primate endometrium.

  2001cites this paper
• Chemical synthesis of 16beta-propylaminoacyl derivatives of estradiol and their inhibitory potency on type 1 17beta-hydroxysteroid dehydrogenase and binding affinity on steroid receptors.

  2001cites this paper
• Structure-based phylogenetic analysis of short-chain alcohol dehydrogenases and reclassification of the 17beta-hydroxysteroid dehydrogenase family.

  2001cites this paper
• The selective estrogen enzyme modulator (SEEM) in breast cancer.

  2001cites this paper
• Inhibitors of type II 17β-hydroxysteroid dehydrogenase

  2001cites this paper
• Structure-activity relationships of 17alpha-derivatives of estradiol as inhibitors of steroid sulfatase.

  2000cites this paper
• Solid-phase synthesis of phenolic steroids: from optimization studies to a convenient procedure for combinatorial synthesis of biologically relevant estradiol derivatives.

  2000cites this paper
• Solid-phase synthesis of hydroxysteroid derivatives using the diethylsilyloxy linker.

  2000cites this paper
• Androsterone 3β-substituted derivatives as inhibitors of type 3 17β-hydroxysteroid dehydrogenase

  2000cites this paper
• N-Butyl-N-methyl-11-(3'-hydroxy-21',17'-carbolactone-19'-nor-17'α-pregna-1',3',5'(10')-trien-7'α-yl)-undecanamide: an inhibitor of type 2 17β-hydroxysteroid dehydrogenase that does not have oestrogenic or androgenic activity

  2000cites this paper
• Androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase.

  2000cites this paper
• Efficient coupling and solid-phase synthesis of steroidal ketone derivative using polymer-bound glycerol

  2000cites this paper
• N-Butyl-N-methyl-11-(3'-hydroxy-21', 17'-carbolactone-19'-nor-17'alpha-pregna-1',3', 5'(10')-trien-7'alpha-yl)-undecanamide: an inhibitor of type 2 17beta-hydroxysteroid dehydrogenase that does not have oestrogenic or androgenic activity.

  2000cites this paper
• O-Methoxycarbonyl Cyanohydrin as a New Protective Group for Carbonyls

  2000cites this paper
• Steroids: reactions and partial synthesis.

  2000cites this paper
• The study of crystallization of estrogenic 17beta-hydroxysteroid dehydrogenase with DHEA and DHT at elevated temperature.

  2000cites this paper
• 17α-Alkan (or alkyn) amide derivatives of estradiol as inhibitors of steroid-sulfatase activity

  1999cites this paper
• Spironolactone-related inhibitors of type II 17beta-hydroxysteroid dehydrogenase: chemical synthesis, receptor binding affinities, and proliferative/antiproliferative activities.

  1999cites this paper
• Effect of Medrogestone on 17β-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines

  1999cites this paper
• Prospects for the treatment of endocrine-responsive tumours.

  1999cites this paper
• Solid-phase synthesis of phenolic steroids: Towards combinatorial libraries of estradiol derivatives

  1999cites this paper
• Effect of Medrogestone on 17beta-hydroxysteroid dehydrogenase activity in the hormone-dependent MCF-7 and T-47D human breast cancer cell lines.

  1999cites this paper
• Two non-reactive ternary complexes of estrogenic 17beta-hydroxysteroid dehydrogenase: crystallization and preliminary structural analysis.

  1999cites this paper
• 17-β HYDROXYSTEROID DEHYDROGENASE TYPES 1 AND 2

  1999cites this paper